

Clarke, Modet & C^o COLOMBIA	ESCOBAR - URIBE ASOCIADOS Intellectual Property
--	---

As. 2955/PCT.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES

E. S. D.

Ref.: Expediente No. 06.037.927
Solicitud de Patente a nombre de
ALZA CORPORATION

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 06-037927-00005-0000
Fecha: 2008-05-15 15:00:42 Dep. 2020 NUEVACREACIONES
Tra. 11 PATENTE/II Lvs: 379 FASENACIONALES
Act. 538 PETICIÓN Folios 5

Yo, **JIMENA ESCOBAR URIBE**, identificada como aparece al pie de mi firma, domiciliada en Bogotá, en la Carrera 11 No. 86-53, piso 6, obrando como apoderada de la sociedad **ALZA CORPORATION**, con domicilio en Mountain View, California, Estados Unidos de América, solicitante de la patente de la referencia, pido a usted que se proceda a examinar si la invención, cuya patente se tramita en el expediente de la referencia, es patentable.

Adjunto al presente memorial los recibos Nos. 08-31,123 de 21 de abril de 2008, 08-32,105 de 21 de abril de 2008, 08-35,564 de 6 de mayo de 2008, 08-35,566 de 6 de mayo de 2008 , por la suma de \$211.000.00, con lo cual queda cubierta la tasa oficial correspondiente a dicho estudio.

Señor Superintendente,


JIMENA ESCOBAR URIBE
C.C.39.779.452 de Usaquén
T.P. 68.228 

154

184

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176085

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 06-037927- -00005-0000

Fecha: 2008-05-15 15:00:42 Dep: 2020 NUEGLACIONE
Tra: 11 PATENTEIYII Eve: 379 FASENACIONALII
Act: 538 PETICION Folios: 5

CERTIFICACION DE EXCEDENTE : 08 - 32,123
FECHA : ABRIL 21 DE 2008

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CLARKE MUDET Y CO. COLOMB	CONSIGNACION	BANCO DE BOGOTA	062754387	126010	21/04/2008	23,492,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-09	OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVICIOS ADMINISTRATIVOS
			120,000.00
		TOTAL :	\$ 120,000.00

SON: CIENTO VEINTE MIL PESOS

RESPONSABLE :

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

2915

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA
COMO PARTE DE LA CANCELACION DE UNA TARIFA VIGENTE Y NO PODRA SER
SUSTITUIDA POR NINGUN RECIBO.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 06-037927- -00005-0000

Fecha 2008-05-15 15:00:42 Dep. 2020 NUCREACIONE
Ira 11 PATENTE IYII Eve. 379 FASE NACIONAL II
Act. 538 PETICION Folios. 5

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 08 - 32,105
FECHA : ABRIL 21 DE 2008

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MOSSET Y CO. COLOMBIA	CONSIGNACION	BANCO DE BOGOTA	062754387	134619	21/04/2008	23,492,000.00

***** CONCEPTO *****

CANT.	ANALITICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-09	OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVICIOS ADMINISTRATIVOS
			TOTAL : 5
			81,000.00
			91,000.00

SON: OCHENTA Y UNO MIL PESOS

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA
COMO PARTE DE LA CANCELACION DE UNA TARIFA VIGENTE Y NO PODRA SER
SUSTITUIDA POR NINGUN RECIBO.

156

156

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 06-037927- -00005-0000

Fecha: 2008-05-15 15:00:42 Dep 2020 NUECREACION
Ira. 11 PATENTE I/II Eje 379 FASE NACIONAL II
Act. 538 PETICION Folios: 5

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 00 - 35,564
FECHA : MAYO 6 DE 2008

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CLARKE MOET Y CO. COLOMBIA	CONSIGNACION	BANCO DE BOGOTA	062754387	693055	06/05/2008	14,897,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-09	OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVICIOS ADMINISTRATIVOS
			TOTAL :
			\$ 5,000.00

SON: CINCO MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA
COMO PARTE DE LA CANCELACION DE UNA TARIFA VIGENTE Y NO PODRA SER
SUSTITUIDA POR NINGUN RECIBO.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 06-037927-00005-0000

Fecha: 2008-05-15 15:00:42 Dep. 2020 NUECREACION
Tra. 11 PATENTE(II) Eje. 379 FASENACIONAL(II)
Act. 538 PETICION Folios: 5

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 08 - 35,566

FECHA : MAYO 6 DE 2008

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CLARKE MODET Y CO. COLOMB	CONSIGNACION	BANCO DE BOGOTA	062754387	693055	06/05/2008	14,897,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-09	OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVICIOS ADMINISTRATIVOS
			TOTAL :
			5,000.00
			5,000.00

SON: CINCO MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

DIVISIÓN DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No. 06-37927

EL EXTRACTO DE LA PRESENTE SOLICITUD DE **PATENTE DE INVENCION**

FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No **582** DE

FECHA **30 DE NOVIEMBRE DE 2007** EL TÉRMINO HÁBIL SEÑALADO POR LA

LEY EXPIRA EL **27 DE FEBRERO DE 2008**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____

NO X

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number
WO 01/51040 A1

- (51) International Patent Classification: **A61K 9/22**, 9/24, 9/32, 9/36
- (21) International Application Number: PCT/US01/00637
- (22) International Filing Date: 9 January 2001 (09.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/175,827 13 January 2000 (13.01.2000) US
- (71) Applicant (for all designated States except US): **LABORATORIOS PHOENIX U.S.A., INC.** [US/US]; 1 Boca Place, 2255 Glades Rd., Suite 324A, Boca Raton, FL 33431 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **FAOUR, Joaquina** [AR/AR]; Ollerios 2312, 8°B, 1426 Buenos Aires (AR). **VERGEZ, Juan, A.** [AR/AR]; Uriburu 1316, 1642 Becar, Buenos Aires 1642 (AR).
- (74) Agent: **MATOS, Rick**; Innovar, L.L.C., P.O. Box 250647, Plano, TX 75025-0647 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/51040 A1

(54) Title: OSMOTIC DEVICE CONTAINING ALPRAZOLAM AND AN ANTIPSYCHOTIC AGENT

(57) Abstract: The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One preferred embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external coat is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.

160
160

- 8 -

Time (h)	Percent Released
0	0
1	13
3	28
6	44
8	52
10	61
12	67
15	76
18	82

An osmotic device according to the invention will generally provide an alprazolam release profile as follows:

Time (h)	Percent Released
0	0
1	10-20
3	25-40
6	40-60
8	50-70
10	60-80
12	65-85
15	75-90
18	80-100

- 5 The osmotic device of Example 2 was administered to a group of volunteers and the pharmacokinetic and pharmacodynamic parameters determined. FIG. 5 depicts the *in vivo* plasma concentration profile for APZ as provided by the osmotic device made according to example 2. Generally after a single dose, the target C_{max} for the alprazolam is about 1.5 ng/ml, or about 0.8-60 ng/ml or about 5-30 ng/ml, with a T_{max} of about 11 ± 4 hours or about
- 10 7-15 hours. The plasma profile depicted in FIG. 5 can be described as follows:

161

- 23 -

295.40; Schizoaffective Disorder 295.70; Schizoaffective Disorder of the Depressive Type; and Major Depressive Disorder with Psychotic Features 296.24, 296.34.

Psychoses are often associated with other diseases and conditions, or caused by such other conditions. For example, they are associated with neurological conditions, endocrine conditions, metabolic conditions, fluid or electrolyte imbalances, hepatic or renal diseases, and autoimmune disorders with central nervous system involvement. Psychoses may also be associated with use or abuse of certain substances. These substances include, but are not limited to cocaine, methylphenidate, dexamethasone, amphetamine and related substances, cannabis, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics and anxiolytics. Psychotic disorders may also occur in association with withdrawal from certain substances. These substances include, but are not limited to, sedatives, hypnotics and anxiolytics. The embodiments of the present invention are useful for treatment of psychotic conditions associated with any of these conditions.

The above-mentioned diseases and disorders are treated in a mammal by administering one or more of the osmotic devices described herein. Each osmotic device is designed for once-daily administration. A patient receiving the osmotic devices will generally be administered one osmotic-device daily for a period of days, week, months or years to be determined by the prescribing physician. Generally, the period is at least one week.

The following examples should not be considered exhaustive, but merely illustrative of only a few of the many embodiments contemplated by the present invention. The methods described herein can be followed to prepare osmotic devices according to the invention.

EXAMPLE 1

A large scale batch of alprazolam (1 mg strength) tablets was prepared by mixing 0.950 g of Alprazolam, 7.00 g of hydroxypropyl methylcellulose 2208, 114.00 g of sodium chloride, 58.45 g of microcrystalline cellulose, 30.0 g of povidone, 80.00 g of polyethylene oxide (molecular weight of about 300,000). The mixture was wet with a blend of 110.00 ml of alcohol 96° and 1.40 g of Polysorbate 20. The blend was granulated and dried at 40 – 50°C for 3 hours; then, it was screened and mixed with 3.80 g of colloidal silicon dioxide. The blend was mixed to homogeneity and 4.40 g of magnesium stearate was added as

162 162

- 24 -

lubricant. The final blend was tabletted using biconcaves, 9.00-mm diameter punches. Cores weight: 300.0 mg. Hardness from 8 to 12 kp.

A first composition to cover the cores was prepared as follows: 36.90 g of cellulose acetate and 1.95 g of polyethylene glycol 400 in a mixture of 493 ml of methylene chloride and 122 ml of methyl alcohol. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane coating weighed 38.9 mg approximately. A 0.75-mm hole was drilled through the coating in one face of the tablet.

The third composition was prepared by mixing 3.00 g of copolyvidone, 3.48 g of titanium dioxide, 8.51 g of talc and 7.00 mg of Aluminum Lake Brilliant Blue in isopropyl alcohol. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane coating weighed 15 mg approximately.

The rapid release external coating was prepared by mixing 0.05 g of alprazolam, 442.05 g of microcrystalline cellulose, 31.40 g of povidone, 18.20 g of crospovidone and 3.30 g of colloidal silicon dioxide. The mixture was blended to homogeneity; then, 5.00 g of magnesium stearate was added as lubricant. This blend was applied over the film-coated tablets by compression using biconcaves, 14.0-mm diameter punches. Coating weight: 500 mg. Hardness from 8 to 14 kp.

The final coating was prepared by mixing 12.1 g of hydroxypropyl methylcellulose 2910, 3.5 g of polyethylene glycol 6000 and 4.40 g of titanium dioxide in a mixture of methylene chloride-alcohol 96° 70:30 v/v (volume/volume). This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane coating weighed 20 mg approximately.

Tablets made according to the above procedure will generally have the following composition.

Component x 1 tablet	0.5 mg	1.0 mg	2.0 mg
<i>CORE</i>			
Alprazolam	0.475 mg	0.950 mg	1.900 mg
Polysorbate 20	0.700 mg	1.400 mg	2.800 mg
Microcrystalline Cellulose	29.225 mg	58.450 mg	116.900 mg
Sodium Chloride	57.000 mg	114.000 mg	228.000 mg
Povidone	15.000 mg	30.000 mg	60.000 mg

163
263

- 25 -

Polyethylene Oxide	40.000 mg	80.000 mg	160.000 mg
Hydroxypropyl methylcellulose 2208	3.500 mg	7.000 mg	14.000 mg
Colloidal Silicon Dioxide	1.900 mg	3.800 mg	7.600 mg
Magnesium Stearate	2.200 mg	4.400 mg	8.800 mg

COATING A

Cellulose Acetate	22.000 mg	36.900 mg	51.900 mg
Polyethylene Glycol 400	1.160 mg	1.950 mg	2.740 mg

COATING B

Copolyvidone	2.000 mg	3.000 mg	4.400 mg
Titanium Dioxide	1.650 mg	3.480 mg	5.100 mg
Talc	6.345 mg	8.513 mg	12.490 mg
Aluminium Lake Brilliant Blue	0.005 mg	0.007 mg	0.010 mg

COATING C

Alprazolam	0.025 mg	0.050 mg	0.100 mg
Microcrystalline Cellulose	309.375 mg	442.050 mg	618.900 mg
Povidone	22.000 mg	31.400 mg	43.900 mg
Crospovidone	12.800 mg	18.200 mg	25.500 mg
Colloidal Silicon Dioxide	2.300 mg	3.300 mg	4.600 mg
Magnesium Stearate	3.500 mg	5.000 mg	7.000 mg

COATING D

Hydroxypropylmethylcellulose 2910	9.100 mg	12.100 mg	15.100 mg
Polyethylene Glycol 6000	2.590 mg	3.500 mg	4.400 mg
Titanium Dioxide	3.310 mg	4.400 mg	5.500 mg

EXAMPLE 2

A large scale batch of Alprazolam (2 mg strength) and Risperidone (5 mg strength) tablets was prepared by mixing 2.00 g of Alprazolam, 14.00 g of Hydroxypropyl methylcellulose 2208, 228.00 g of Sodium Chloride, 116.80 g of Microcrystalline Cellulose, 60.0 g of Povidone, 160.00 g of Polyethylene Oxide (molecular weight of about 300,000). The mixture was wet with a blend of 110.00 ml of alcohol 96° and 2.80 g of Polysorbate 20. The blend was granulated and dried at 40 – 50°C for 3 hours; then, it was screened and mixed with 7.60 g of Colloidal Silicon Dioxide. The blend was mixed to homogenize and 8.80 g of Magnesium Stearate was added as lubricant. The final blend was tabletted using biconcaves, 10.50-mm diameter punches. Cores weight: 600.0 mg. Hardness from 8 to 12 kp.

164
164

- 26 -

A first composition to cover the cores was prepared as follows: 51.90 g of Cellulose Acetate and 2.74 g of Polyethylene Glycol 400 in a mixture of 493 ml of Methylene Chloride and 122 ml of Methyl Alcohol. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane coating weighed 54.6 mg approximately. A 0.75-mm hole was drilled through the coating in one face of the tablet.

The third composition was prepared by mixing 4.40 g of Copolyvidone, 5.10 g of Titanium Dioxide, 12.49 g of Talc and 10.00 mg of Aluminum Lake Brilliant Blue in Isopropyl Alcohol. This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane coating weighed 22 mg approximately.

The rapid release external coating was prepared by mixing 5.00 g of Risperidone, 594.36 g of Microcrystalline Cellulose, 50.30 g of Povidone, 32.25 g of Crospovidone and 4.72 g of Colloidal Silicon Dioxide. The mixture was blended to homogenize; then, 13.37 g of Magnesium Stearate was added as lubricant. This blend was applied over the film-coated tablets by compression using biconcaves, 14.0-mm diameter punches. Coating weight: 700 mg. Hardness from 8 to 15 kp.

The final coating was prepared by mixing 27.27 g of Hydroxypropyl methylcellulose 2910, 7.77 g of Polyethylene Glycol 6000, 9.96 g of Titanium Dioxide in a mixture of Methylene Chloride-Alcohol 96° 70:30 v/v (volume/volume). This polymer mixture was sprayed onto the tablets in a conventional pan coater to obtain film-coated tablets which membrane coating weighed 30 mg approximately.

Tablets made according to the above-described procedure generally have a formulation as follows:

CORE

Alprazolam	2.000 mg
Polysorbate 20	2.800 mg
Microcrystalline Cellulose	116.800 mg
Sodium Chloride	228.000 mg
Povidone	60.000 mg
Polyethylene Oxide	160.000 mg
Hydroxypropyl methylcellulose 2208	14.000 mg
Colloidal Silicon Dioxide	7.600 mg
Magnesium Stearate	8.800 mg

165
~~165~~

- 27 -

CORE**COATING A**

Cellulose Acetate	51.900 mg
Polyethylene Glycol 400	2.740 mg

COATING B

Copolyvidone	4.400 mg
Titanium Dioxide	5.100 mg
Talc	12.490 mg
Aluminium Lake brilliant Blue	0.010 mg

COATING D

Risperidone	5.000 mg
Microcrystalline Cellulose	597.360 mg
Povidone	50.300 mg
Crospovidone	32.250 mg
Colloidal Silicon Dioxide	4.720 mg
Magnesium Stearate	13.370 mg

COATING E

Hydroxypropylmethylcellulose 2910	18.180 mg
Polyethylene Glycol 6000	5.180 mg
Titanium Dioxide	6.640 mg

EXAMPLE 3

The procedure of Example 2 is used to prepare osmotic devices having the following general composition.

Core

Alprazolam		0.5-5.0 mg
Polysorbate 20 (Wetting Agent)		0.1-5.0 mg
Microcrystalline Cellulose (Filler)		50-200 mg
Sodium Chloride (Osmagent)		150-300 mg
Povidone (binder)		10-100 mg
Polyethylene Oxide (Osmopolymer)		130-190 mg
Hydroxypropyl methylcellulose (Viscosity increasing agent)	2208	10-200 mg
Colloidal Silicon Dioxide (Glidant)		2.5-10 mg
Magnesium Stearate (Lubricant)		5-10 mg

Semipermeable Coat

Cellulose Acetate (Cellulose ester)	20-75 mg
Polyethylene Glycol 400 (Plasticizer)	1-4 mg

166
~~166~~

- 28 -

First Inert Water Soluble Coat

Copolyvidone (Water soluble polymer)	2-10 mg
Titanium Dioxide (Opaquant)	1-20 mg
Talc (Filler, Opaquant)	0-18 mg
Aluminum Lake Brilliant Blue (Colorant)	0.001-0.02 mg

Anti-psychotic Agent-containing Coat

Risperidone (Anti-psychotic agent)	2.5-7.5 mg
Microcrystalline Cellulose (filler)	300-700 mg
Povidone (Binder)	10-80 mg
Crospovidone (Disintegrant)	25-40 mg
Colloidal Silicon Dioxide (Glidant)	1-7 mg
Magnesium Stearate (Lubricant)	4-10.5 mg

Finish Coat (optional)

Hydroxypropyl methylcellulose 2910 (Water soluble polymer)	12-25 mg
Polyethylene Glycol 6000 (Plasticizer)	2-7 mg
Titanium Dioxide (Opaquant)	3.5-10 mg

The above is a detailed description of particular embodiments of the invention. It is recognized that departures from the disclosed embodiments may be made within the scope of the invention and that obvious modifications will occur to a person skilled in the art. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed herein and still obtain a like or similar result without departing from the spirit and scope of the invention. All of the embodiments disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure.

167

167

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIRECCION DE NUEVAS CREACIONES

2020
Bogotá, D.C.,

Abogada
Jimena ESCOBAR URIBE
Apoderada

ASUNTO	Radicación	06-037927
	Trámite	011
	Evento	379
	Actuación	430
	Oficio	008791
	Folios	169

Patente de Invención	☒	Patente de Modelo de Utilidad	☐
Vía Nacional	☐		
Vía PCT (fase nacional)	☒	Cap. I	☐
		Cap. II	☒
No. Sol. Internacional	PCT/US2004/031394		
Fecha de Presentación Interna.	2004/09/24		

Como resultado del examen de fondo, realizado con fundamento en el artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica:

1. Documentos estudiados

Descripción: Folios: 11 a 88

Reivindicaciones: Folios 89 a 97 como se radicó inicialmente

Prioridad: Fecha: 2003/09/26, 2003/12/05, país: US y número: 60/506.544, 60/527,434

2. Objeto de la invención

- Título de la solicitud: Formas de dosificación osmóticas para el suministro controlado de alprazolam. Número de folio: 1

El problema planteado en esta solicitud es la necesidad de encontrar una forma de dosificación una vez al día, de alprazolam en los trastornos de ansiedad generalizados que reduzca los efectos secundarios de sedación y potencial abuso.

Para solucionar este problema técnico la solicitud en estudio proporciona una forma de dosificación de liberación sostenida que proporciona mediante la

dosificación una vez al día una concentración de alprazolam de plasma de estado estable promedio terapéuticamente efectiva.

Clasificación Internacional de Patentes (IPC.): A61K 9/22

3. De la solicitud de Patente

Reivindicaciones (artículo 30 D 486)

Una vez revisado el capítulo reivindicatorio esta dependencia encuentra:

- Reivindicación 10, 21, 34: De acuerdo a lo objetado anteriormente, la presente reivindicación no se acepta tal como aparece.
- Se observa de forma generalizada que se está caracterizando una forma de dosificación por su régimen de disolución o liberación o C_{max} en plasma, o área bajo la curva, lo cual es inaceptable ya que son los resultados a esperar o las ventajas de la misma no las características esenciales de la composición o forma farmacéutica que se pretende reivindicar, por lo tanto solo se tendrá en cuenta la parte caracterizante que corresponde a los componentes y la estructura de la misma.
- Reivindicación 44 -48: Se reivindican formas de dosificación por su posterior uso, lo cual no puede aceptarse.

4. Determinación del Estado de la Técnica

La fecha que se ha tenido en cuenta para determinar el Estado de la Técnica es:

Fecha de presentación de la solicitud prioritaria 2003/09/26

Teniendo en cuenta la fecha indicada se realizó la búsqueda en el estado de la técnica de documentos relacionados con la solicitud encontrándose los siguientes documentos más relevantes:

Nº	Documento	Título	Fecha de publicación*
D ₁	WO 01/51040	OSMOTIC DEVICE CONTAINING ALPRAZOLAM AND AN ANTIPSYCHOTIC AGENT	2001/07/19

5. Análisis de patentabilidad (artículo 14 D486)

Novedad (artículo 16 D486)

Reivindicación 1: Forma de dosificación que comprende una dosis de alprazolam

D₁ enseña forma de dosificación osmótica de alprazolam, para entrega lenta o controlada del fármaco. Comprende un núcleo comprimido (folio 165) conformado por gránulos que contienen polietilén óxido como osmopolímero, NaCl, como osmoagente, PVP y HPMC como ligantes, y estearato de Magnesio; una pared semipermeable (folio 165) que la rodea conformada por acetato de celulosa y PEG, una capa de fármaco (folio 165) que comprende alprazolam y un orificio de salida en la pared semipermeable (ver abstract). La forma de

dosificación está dispuesta para entrega de una vez al día y el T_{máx} está en el rango de 7-15 horas.

TABLA 1	
CARACTERÍSTICAS REIVINDICADAS	D ₁
dosis de alprazolam	Si

Folio 165

- ♦ Por lo tanto los elementos característicos de la forma de dosificación de la reivindicación 1, es decir: una forma de dosificación con alprazolam, habían sido divulgados previamente en el Estado de la Técnica.

De manera que el objeto de esta solicitud, tal como aparece en las reivindicaciones 1 - 48, no es nuevo.

6. Conclusión:

Los requisitos de patentabilidad de la presente solicitud se encuentran afectados así:

Nº	Documento Nº	Reivindicaciones afectadas	Requisito que afecta
D ₁	WO 01/51040	1 - 48	NOVEDAD

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de 60 días contados a partir de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única Nº 10 de 2001.

ALIX CARMENZA CÉSPEDES DE VERGEL
Directora de Nuevas Creaciones (C)

El anterior requerimiento fue notificado por fijación en lista, de fecha
09 JUL. 2010

CONCEPTO TÉCNICO No. 1124	EXAMINADOR TÉCNICO Código No. 202087
-------------------------------------	--